Basic information Safety Supplier Related

nimotuzumab

Basic information Safety Supplier Related

nimotuzumab Basic information

Product Name:
nimotuzumab
Synonyms:
  • nimotuzumab
  • Research Grade Nimotuzumab(DHB86914)
CAS:
828933-51-3
MW:
0
Mol File:
Mol File
More
Less

nimotuzumab Usage And Synthesis

Description

Overexpression of epidermal growth factor receptor (EGFR), a transmembrane receptor tyrosine kinase, is prevalent in malignant tumors of epithelial origin and is especially common in breast, head and neck, colon, and lung cancer. With EGFR overexpression, prognosis is poor due to associated tumor invasion, metastasis, enhanced angiogenesis, and resistance to chemotherapy; thus, modulation of EGFR-mediated signaling is an attractive target for intervention. Small-molecule kinase inhibitors (gefitinib and erlotinib) and a monoclonal antibody (cetuximab) specific for EGFR are in clinical evaluation, but treatment cessation due to development of severe acne-like rash is common with these EGFR antagonists. Notably, nimotuzumab, a humanized form of the murine IgG2a monoclonal antibody that has been launched in India for treatment of head and neck cancers overexpressing EGFR, demonstrates clinical efficacy devoid of the rash toxicity. .

Originator

Center for Molecular Immunology (Cuba)

brand name

BioMab EFGR, Theraloc

nimotuzumabSupplier

LGM Pharma
Tel
1-(800)-881-8210
Email
inquiries@lgmpharma.com
NCE Biomedical Co.,Ltd.
Tel
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
SPIRO PHARMA
Tel
Email
eric_feng1954@126.com
Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Email
info@efebio.com
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Email
2853530910@QQ.com